fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 28, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

EAP criteria for other products
Exceptional Access criteria on record are for Brand(s): Dupixent; DOSAGE FORM/ STRENGTH: 200 mg/ 1.14 mL Prefilled syringe and prefilled pen, — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Dupilumab Brand(s): Dupixent DOSAGE FORM/ STRENGTH: 200 mg/ 1.14 mL Prefilled syringe and prefilled pen, 300 mg/ 2mL prefilled syringe and prefilled pen Effective Date: May 17, 2023 Initiation Criteria: For the treatment of severe asthma in patients meeting the following criteria; 1. Patient is aged 6 years old or older; AND 2. Dupilumab is being used as an add-on maintenance therapy; AND 3. Patients 6 to 11 years of age with a type 2 or eosinophilic phenotype and a documented blood eosinophil count equal to or greater than 150 cells/µL within the past 12 months OR Patients 12 years of age or older with a type 2 or eosinophilic phenotype and a documented blood eosinophil count equal to or greater than 150 cells/µL within the past 12 months and/or has oral corticosteroid (OCS) dependent asthma; AND 60 Dupilumab Brand(s): Dupixent DOSAGE FORM/ STRENGTH: 200 mg/1.14 mL and 300mg/2mL (Prefilled syringe and prefilled pen) 4. Asthma is inadequately controlled using optimal treatment. i) For patients 6 to 11 years of age, this is defined as high dose inhaled corticosteroids (ICS) (greater than or equal to 400 mcg fluticasone priopionate daily or equivalent) alone OR medium- to high dose ICS plus 1 controller (e.g. a long-acting beta-agonists) AND experiencing at least one severe exacerbation (defined as having been treated with a systemic corticosteroid, hospitalized, or having visited an emergency department for worsening asthma) in the past 12 months ii) For patients 12 years and older, this is defined as using high dose ICS (greater than or equal to 500 mcg of fluticasone propionate or equivalent daily), and 1 or more additional asthma controller(s) (e.g., LABAs)1 5. Patient is not using any other biologics to treat asthma; AND 6. A baseline assessment of asthma symptom control using a validated asthma control questionnaire must be completed prior to initiation of dupilumab treatment. 7. Request is submitted by a specialist in respirology, or allergy/clinical immunology, or by a physician with expertise in the treatment of asthma, unless the request confirms that the patient does not have access to such specialists, in which case the request may be submitted by an authorized prescriber. 1Patients with type 2 or eosinophilic phenotypes are considered to be inadequately controlled if they have worsening of asthma resulting in administration of systemic corticosteroids for at least 3 days, or an emergency room visit, or hospitalization, in the past 12 months Renewal criteria: Renewals will be considered on a case-by-case basis for patients 6 years of age or older with type 2 or eosinophilic asthma who do not meet any of the following discontinuation/stopping criteria: 61 Dupilumab Brand(s): Dupixent DOSAGE FORM/ STRENGTH: 200 mg/1.14 mL and 300mg/2mL (Prefilled syringe and prefilled pen) • Patient’s 12-month follow-up asthma control questionnaire score using the same validated asthma control questionnaire completed at baseline does not show improvement, such as a decrease of less than 0.5 points on the ACQ or an increase of less than 3 points on the ACT; • Patient’s subsequent asthma control questionnaire scores have not been maintained at the score seen following the first 12-months of therapy; • The number of clinically significant exacerbations defined as worsening of asthma resulting in administration of systemic corticosteroids, an emergency room visit or hospitalization, has increased within the previous 12 months. Renewals will be considered on a case-by-case basis for patients 12 years of age or older on maintenance treatment with OCS dependent asthma who do not meet any of the following stopping criteria: • there has been no decrease in the OCS dose in the first 12 months of treatment • the reduction in the dose of OCS achieved after the first 12 months of treatment is not maintained or improved subsequently Approval duration of initial and renewals: 1 year 62 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 60, record 40, corpus 2025-01-01; name match only, not an eligibility decision

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

EAP criteria for other products
Exceptional Access criteria on record are for Brand(s): Dupixent; DOSAGE FORM/ STRENGTH: 200mg/1.14mL, 300mg/2ml (Prefilled syringe and — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Dupilumab Brand(s): Dupixent DOSAGE FORM/ STRENGTH: 200mg/1.14mL, 300mg/2ml (Prefilled syringe and prefilled pen) Effective date: May 6, 2021 Updated: December 3, 2021 and December 1, 2022 Updated: April 28, 2023 Initiation Criteria For the treatment of moderate to severe atopic dermatitis in patients meeting the all the following criteria; 1. 12 years of age or older; AND 2. Diagnosed with moderate-to-severe atopic dermatitis (AD) by the Eczema Area and Severity Index (EASI) score equal to or greater than 16 points and the Investigators (Physician) Global Assessment score of 3 to 4; AND 3. Failure to maintain adequate control of their dermatitis with maximally tolerated medical topical therapies for AD combined with phototherapy (where available); (Note 1 and 2) AND 4. Failure to maintain adequate control of their dermatitis with maximally tolerated medical topical therapies for AD combined with at least 1 of the 4 systemic immunomodulators (methotrexate, cyclosporine, mycophenolate mofetil, or azathioprine). (Note 1 and 2). 5. Dupilumab is prescribed by a dermatologist, allergist, pediatrician or clinical immunologist, or in consultation with one of these specialists. (Please include the consult note with the EAP application.) Exclusion Criteria: 1. Dupilumab will not be funded if it is used in combination with phototherapy or any immunomodulatory drugs (including biologics (Note 3) or a Janus kinase [JAK] inhibitor treatment) for treatment of AD. Notes: 1. For each treatment used, provide documentation of refractory disease and/or intolerance (including a description of the adverse effect and severity of reaction). If a patient is deemed to be ineligible or contraindicated to receive the treatment, provide the reason(s) for their ineligibility. 111 Dupilumab Brand(s): Dupixent DOSAGE FORM/ STRENGTH: 200mg/1.14mL, 300mg/2ml Injection solution 2. An adequate trial for patients with AD who undergo therapy with phototherapy, methotrexate, cyclosporine, mycophenolate mofetil, and azathioprine is defined as follows: • For phototherapy: the typical duration would be considered 12 weeks (3 times per week). • For methotrexate: an adequate trial would be 10 mg to 20 mg per week for 12 weeks. • For cyclosporine: an adequate trial would be 2.5 mg/kg to 5 mg/kg per day for 12 weeks. • For mycophenolate mofetil: an adequate trial would be 1 g twice daily for 12 weeks. • For azathioprine: an adequate trial would be 1.5 to 2.5 mg/kg/day for 12 weeks. 3. The concurrent use of dupilumab used in combination with other biologics used for other conditions will be considered on a case-by-case basis. Renewal Criteria: First renewal: Renewal of funding will be considered in patients with documentation of benefit from treatment. Benefit from treatment is defined as a 75% or greater improvement from baseline in the Eczema Area and Severity Index (EASI) score (EASI-75) within six months of treatment initiation. Subsequent renewals: Subsequent renewal of funding will be considered in patient who maintain the 75% or greater improvement in EASI-75 score response from baseline. Duration of Approval for initial requests: 6 months Duration of Approval for first and second renewal: 6 months Duration of Approval for 3rd and subsequent renewals: 1 year Recommended dose: Adults: An initial dose of 600 mg followed by 300 mg every other week. Refer to the product monograph for dosing in adolescents 17 year of age and younger. 112 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 111, record 69, corpus 2025-01-01; name match only, not an eligibility decision
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Dupilumab: not an ODB benefit — Exceptional Access criteria on file (2 indications). EAP application required.

ODB status: not listed in this extract Write on the script: Exceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗)
Not listed in the Ontario formulary extract (2026-09-22).

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Dupilumab Brand(s): Dupixent DOSAGE FORM/ STRENGTH: 200mg/1.14mL, 300mg/2ml (Prefilled syringe and prefilled pen) Effective date: May 6, 2021 Updated: December 3, 2021 and December 1, 2022 Updated: April 28, 2023 Initiation Criteria For the treatment of moderate to severe atopic dermatitis in patients meeting the all the following criteria; 1. 12 years of age or older; AND 2. Diagnosed with moderate-to-severe atopic dermatitis (AD) by the Eczema Area and Severity Index (EASI) score equal to or greater than 16 points and the Investigators (Physician) Global Assessment score of 3 to 4; AND 3. Failure to maintain adequate control of their dermatitis with maximally tolerated medical topical therapies for AD combined with phototherapy (where available); (Note 1 and 2) AND 4. Failure to maintain adequate control of their dermatitis with maximally tolerated medical topical therapies for AD combined with at least 1 of the 4 systemic immunomodulators (methotrexate, cyclosporine, mycophenolate mofetil, or azathioprine). (Note 1 and 2). 5. Dupilumab is prescribed by a dermatologist, allergist, pediatrician or clinical immunologist, or in consultation with one of these specialists. (Please include the consult note with the EAP application.) Exclusion Criteria: 1. Dupilumab will not be funded if it is used in combination with phototherapy or any immunomodulatory drugs (including biologics (Note 3) or a Janus kinase [JAK] inhibitor treatment) for treatment of AD. Notes: 1. For each treatment used, provide documentation of refractory disease and/or intolerance (including a description of the adverse effect and severity of reaction). If a patient is deemed to be ineligible or contraindicated to receive the treatment, provide the reason(s) for their ineligibility. 111 Dupilumab Brand(s): Dupixent DOSAGE FORM/ STRENGTH: 200mg/1.14mL, 300mg/2ml Injection solution 2. An adequate trial for patients with AD who undergo therapy with phototherapy, methotrexate, cyclosporine, mycophenolate mofetil, and azathioprine is defined as follows: • For phototherapy: the typical duration would be considered 12 weeks (3 times per week). • For methotrexate: an adequate trial would be 10 mg to 20 mg per week for 12 weeks. • For cyclosporine: an adequate trial would be 2.5 mg/kg to 5 mg/kg per day for 12 weeks. • For mycophenolate mofetil: an adequate trial would be 1 g twice daily for 12 weeks. • For azathioprine: an adequate trial would be 1.5 to 2.5 mg/kg/day for 12 weeks. 3. The concurrent use of dupilumab used in combination with other biologics used for other conditions will be considered on a case-by-case basis. Renewal Criteria: First renewal: Renewal of funding will be considered in patients with documentation of benefit from treatment. Benefit from treatment is defined as a 75% or greater improvement from baseline in the Eczema Area and Severity Index (EASI) score (EASI-75) within six months of treatment initiation. Subsequent renewals: Subsequent renewal of funding will be considered in patient who maintain the 75% or greater improvement in EASI-75 score response from baseline. Duration of Approval for initial requests: 6 months Duration of Approval for first and second renewal: 6 months Duration of Approval for 3rd and subsequent renewals: 1 year Recommended dose: Adults: An initial dose of 600 mg followed by 300 mg every other week. Refer to the product monograph for dosing in adolescents 17 year of age and younger. 112 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 111, record 69, corpus 2025-01-01; name match only, not an eligibility decision Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Dupilumab Brand(s): Dupixent DOSAGE FORM/ STRENGTH: 200 mg/ 1.14 mL Prefilled syringe and prefilled pen, 300 mg/ 2mL prefilled syringe and prefilled pen Effective Date: May 17, 2023 Initiation Criteria: For the treatment of severe asthma in patients meeting the following criteria; 1. Patient is aged 6 years old or older; AND 2. Dupilumab is being used as an add-on maintenance therapy; AND 3. Patients 6 to 11 years of age with a type 2 or eosinophilic phenotype and a documented blood eosinophil count equal to or greater than 150 cells/µL within the past 12 months OR Patients 12 years of age or older with a type 2 or eosinophilic phenotype and a documented blood eosinophil count equal to or greater than 150 cells/µL within the past 12 months and/or has oral corticosteroid (OCS) dependent asthma; AND 60 Dupilumab Brand(s): Dupixent DOSAGE FORM/ STRENGTH: 200 mg/1.14 mL and 300mg/2mL (Prefilled syringe and prefilled pen) 4. Asthma is inadequately controlled using optimal treatment. i) For patients 6 to 11 years of age, this is defined as high dose inhaled corticosteroids (ICS) (greater than or equal to 400 mcg fluticasone priopionate daily or equivalent) alone OR medium- to high dose ICS plus 1 controller (e.g. a long-acting beta-agonists) AND experiencing at least one severe exacerbation (defined as having been treated with a systemic corticosteroid, hospitalized, or having visited an emergency department for worsening asthma) in the past 12 months ii) For patients 12 years and older, this is defined as using high dose ICS (greater than or equal to 500 mcg of fluticasone propionate or equivalent daily), and 1 or more additional asthma controller(s) (e.g., LABAs)1 5. Patient is not using any other biologics to treat asthma; AND 6. A baseline assessment of asthma symptom control using a validated asthma control questionnaire must be completed prior to initiation of dupilumab treatment. 7. Request is submitted by a specialist in respirology, or allergy/clinical immunology, or by a physician with expertise in the treatment of asthma, unless the request confirms that the patient does not have access to such specialists, in which case the request may be submitted by an authorized prescriber. 1Patients with type 2 or eosinophilic phenotypes are considered to be inadequately controlled if they have worsening of asthma resulting in administration of systemic corticosteroids for at least 3 days, or an emergency room visit, or hospitalization, in the past 12 months Renewal criteria: Renewals will be considered on a case-by-case basis for patients 6 years of age or older with type 2 or eosinophilic asthma who do not meet any of the following discontinuation/stopping criteria: 61 Dupilumab Brand(s): Dupixent DOSAGE FORM/ STRENGTH: 200 mg/1.14 mL and 300mg/2mL (Prefilled syringe and prefilled pen) • Patient’s 12-month follow-up asthma control questionnaire score using the same validated asthma control questionnaire completed at baseline does not show improvement, such as a decrease of less than 0.5 points on the ACQ or an increase of less than 3 points on the ACT; • Patient’s subsequent asthma control questionnaire scores have not been maintained at the score seen following the first 12-months of therapy; • The number of clinically significant exacerbations defined as worsening of asthma resulting in administration of systemic corticosteroids, an emergency room visit or hospitalization, has increased within the previous 12 months. Renewals will be considered on a case-by-case basis for patients 12 years of age or older on maintenance treatment with OCS dependent asthma who do not meet any of the following stopping criteria: • there has been no decrease in the OCS dose in the first 12 months of treatment • the reduction in the dose of OCS achieved after the first 12 months of treatment is not maintained or improved subsequently Approval duration of initial and renewals: 1 year 62 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 60, record 40, corpus 2025-01-01; name match only, not an eligibility decision
Patient pays: program not supplied; amount cannot be determined.
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95935
Health Canada: Marketed since 2018-02-06 · brand DUPIXENT · ATC D11AH05 DUPILUMAB · form Solution · route Subcutaneous · ingredients DUPILUMAB 300 MG/2ML · company Sanofi-aventis canada inc · schedule Prescription, Schedule d

Check on the official e-Formulary (paste DIN 02470365)

Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98251
Health Canada: Marketed since 2019-11-29 · brand DUPIXENT · ATC D11AH05 DUPILUMAB · form Solution · route Subcutaneous · ingredients DUPILUMAB 200 MG/1.14ML · company Sanofi-aventis canada inc · schedule Prescription, Schedule d

Check on the official e-Formulary (paste DIN 02492504)

Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99930
Health Canada: Marketed since 2021-05-27 · brand DUPIXENT · ATC D11AH05 DUPILUMAB · form Solution · route Subcutaneous · ingredients DUPILUMAB 300 MG/2ML · company Sanofi-aventis canada inc · schedule Prescription, Schedule d

Check on the official e-Formulary (paste DIN 02510049)

Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101328
Health Canada: Marketed since 2022-06-23 · brand DUPIXENT · ATC D11AH05 DUPILUMAB · form Solution · route Subcutaneous · ingredients DUPILUMAB 200 MG/1.14ML · company Sanofi-aventis canada inc · schedule Prescription, Schedule d

Check on the official e-Formulary (paste DIN 02524252)

1 discontinued or unmarketed products
Health Canada: Cancelled pre market since 2023-08-15 · brand DUPIXENT · ATC D11AH05 DUPILUMAB · form Solution · route Subcutaneous · ingredients DUPILUMAB 100 MG/0.67ML · company Sanofi-aventis canada inc · schedule Prescription, Schedule d
Source record
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22 DIN 02470365 Shortage status: resolved shortage (ended 2022-04-28); reports as of 2026-10-06T03:13:29.198587+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02470365 DIN 02492504 Shortage status: no shortage or discontinuation reported (checked 2026-10-06T03:13:29.198587+00:00); reports as of 2026-10-06T03:13:29.198587+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02492504 DIN 02510049 Shortage status: no shortage or discontinuation reported (checked 2026-10-06T03:13:29.198587+00:00); reports as of 2026-10-06T03:13:29.198587+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02510049 DIN 02524252 Shortage status: no shortage or discontinuation reported (checked 2026-10-06T03:13:29.198587+00:00); reports as of 2026-10-06T03:13:29.198587+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02524252 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95935 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98251 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99930 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101328 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101530 Health Canada search source: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95935, fetched 2026-10-05 Health Canada search source: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98251, fetched 2026-10-05 Health Canada search source: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99930, fetched 2026-10-05 Health Canada search source: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101328, fetched 2026-10-05 Health Canada search source: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101530, fetched 2026-10-05

Prepare an Exceptional Access request

SADIE has its own form for many drugs; this checklist prepares the answers; the ministry decides. Open SADIE

Use this text in SADIE’s free-text fields or read from it on a Telephone Request Service call. Review marks do not indicate eligibility. Evidence stays in this page until you copy it; nothing entered here is sent or saved. Do not enter patient identifiers.

EAP Telephone Request Service: The TRS can be accessed by calling toll-free at 1-866-811-9893 or 416-327-8109 (Toronto area) between 8:30 a.m. and 5:00 p.m. Monday through Friday (except holidays) and selecting the TRS option. Source; updated September 15, 2026

EAP fax: In Ontario: 1-866-811-9908 or 416-327-7526 (Toronto area). Outside Ontario: 1-833-905-4260. Source; updated September 15, 2026

Posted turnaround and Telephone Request Service scope
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 28, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
Source; updated October 05, 2026

Dupilumab (Dupixent)

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Prepare answers: For the treatment of moderate to severe atopic dermatitis in patients meeting the all the following criteria;

Ministry criteria corpus 2025-01-01; page 111

Dupilumab Brand(s): Dupixent DOSAGE FORM/ STRENGTH: 200mg/1.14mL, 300mg/2ml (Prefilled syringe and prefilled pen) Effective date: May 6, 2021 Updated: December 3, 2021 and December 1, 2022 Updated: April 28, 2023
Initiation Criteria
For the treatment of moderate to severe atopic dermatitis in patients meeting the all the following criteria;
1. 12 years of age or older; AND
2. Diagnosed with moderate-to-severe atopic dermatitis (AD) by the Eczema Area and Severity Index (EASI) score equal to or greater than 16 points and the Investigators (Physician) Global Assessment score of 3 to 4; AND
3. Failure to maintain adequate control of their dermatitis with maximally tolerated medical topical therapies for AD combined with phototherapy (where available); (Note 1 and 2) AND
4. Failure to maintain adequate control of their dermatitis with maximally tolerated medical topical therapies for AD combined with at least 1 of the 4 systemic immunomodulators (methotrexate, cyclosporine, mycophenolate mofetil, or azathioprine). (Note 1 and 2).
5. Dupilumab is prescribed by a dermatologist, allergist, pediatrician or clinical immunologist, or in consultation with one of these specialists. (Please include the consult note with the EAP application.)
Exclusion Criteria:
1. Dupilumab will not be funded if it is used in combination with phototherapy or any immunomodulatory drugs (including biologics (Note 3) or a Janus kinase [JAK] inhibitor treatment) for treatment of AD.
Notes:
1. For each treatment used, provide documentation of refractory disease and/or intolerance (including a description of the adverse effect and severity of reaction). If a patient is deemed to be ineligible or contraindicated to receive the treatment, provide the reason(s) for their ineligibility.
111 Dupilumab Brand(s): Dupixent DOSAGE FORM/ STRENGTH: 200mg/1.14mL, 300mg/2ml Injection solution
2. An adequate trial for patients with AD who undergo therapy with phototherapy, methotrexate, cyclosporine, mycophenolate mofetil, and azathioprine is defined as follows:
• For phototherapy: the typical duration would be considered 12 weeks (3 times per week).
• For methotrexate: an adequate trial would be 10 mg to 20 mg per week for 12 weeks.
• For cyclosporine: an adequate trial would be 2.5 mg/kg to 5 mg/kg per day for 12 weeks.
• For mycophenolate mofetil: an adequate trial would be 1 g twice daily for 12 weeks.
• For azathioprine: an adequate trial would be 1.5 to 2.5 mg/kg/day for 12 weeks.
3. The concurrent use of dupilumab used in combination with other biologics used for other conditions will be considered on a case-by-case basis.
Renewal Criteria:
First renewal:
Renewal of funding will be considered in patients with documentation of benefit from treatment. Benefit from treatment is defined as a 75% or greater improvement from baseline in the Eczema Area and Severity Index (EASI) score (EASI-75) within six months of treatment initiation.
Subsequent renewals:
Subsequent renewal of funding will be considered in patient who maintain the 75% or greater improvement in EASI-75 score response from baseline. Duration of Approval for initial requests: 6 months Duration of Approval for first and second renewal: 6 months Duration of Approval for 3rd and subsequent renewals: 1 year
Recommended dose:
Adults: An initial dose of 600 mg followed by 300 mg every other week.
Refer to the product monograph for dosing in adolescents 17 year of age and younger.
112

Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.

Dupilumab (Dupixent)

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Prepare answers: For the treatment of severe asthma in patients meeting the following criteria;

Ministry criteria corpus 2025-01-01; page 60

Dupilumab Brand(s): Dupixent DOSAGE FORM/ STRENGTH: 200 mg/ 1.14 mL Prefilled syringe and prefilled pen, 300 mg/ 2mL prefilled syringe and prefilled pen Effective Date: May 17, 2023
Initiation Criteria:
For the treatment of severe asthma in patients meeting the following criteria;
1. Patient is aged 6 years old or older; AND
2. Dupilumab is being used as an add-on maintenance therapy; AND
3. Patients 6 to 11 years of age with a type 2 or eosinophilic phenotype and a documented blood eosinophil count equal to or greater than 150 cells/µL within the past 12 months
OR
Patients 12 years of age or older with a type 2 or eosinophilic phenotype and a documented blood eosinophil count equal to or greater than 150 cells/µL within the past 12 months and/or has oral corticosteroid (OCS) dependent asthma; AND
60 Dupilumab Brand(s): Dupixent DOSAGE FORM/ STRENGTH: 200 mg/1.14 mL and 300mg/2mL (Prefilled syringe and prefilled pen)
4. Asthma is inadequately controlled using optimal treatment.
i) For patients 6 to 11 years of age, this is defined as high dose inhaled corticosteroids (ICS) (greater than or equal to 400 mcg fluticasone priopionate daily or equivalent) alone OR medium- to high dose ICS plus 1 controller (e.g. a long-acting beta-agonists) AND experiencing at least one severe exacerbation (defined as having been treated with a systemic corticosteroid, hospitalized, or having visited an emergency department for worsening asthma) in the past 12 months
ii) For patients 12 years and older, this is defined as using high dose ICS (greater than or equal to 500 mcg of fluticasone propionate or equivalent daily), and 1 or more additional asthma controller(s) (e.g., LABAs)1
5. Patient is not using any other biologics to treat asthma; AND
6. A baseline assessment of asthma symptom control using a validated asthma control questionnaire must be completed prior to initiation of dupilumab treatment.
7. Request is submitted by a specialist in respirology, or allergy/clinical immunology, or by a physician with expertise in the treatment of asthma, unless the request confirms that the patient does not have access to such specialists, in which case the request may be submitted by an authorized prescriber. 1Patients with type 2 or eosinophilic phenotypes are considered to be inadequately
controlled if they have worsening of asthma resulting in administration of systemic corticosteroids for at least 3 days, or an emergency room visit, or hospitalization, in the past 12 months
Renewal criteria:
Renewals will be considered on a case-by-case basis for patients 6 years of age or older with type 2 or eosinophilic asthma who do not meet any of the following discontinuation/stopping criteria:
61 Dupilumab Brand(s): Dupixent DOSAGE FORM/ STRENGTH: 200 mg/1.14 mL and 300mg/2mL (Prefilled syringe and prefilled pen)
• Patient’s 12-month follow-up asthma control questionnaire score using the same validated asthma control questionnaire completed at baseline does not show improvement, such as a decrease of less than 0.5 points on the ACQ or an increase of less than 3 points on the ACT;
• Patient’s subsequent asthma control questionnaire scores have not been maintained at the score seen following the first 12-months of therapy;
• The number of clinically significant exacerbations defined as worsening of asthma resulting in administration of systemic corticosteroids, an emergency room visit or hospitalization, has increased within the previous 12 months.
Renewals will be considered on a case-by-case basis for patients 12 years of age or older on maintenance treatment with OCS dependent asthma who do not meet any of the following stopping criteria:
• there has been no decrease in the OCS dose in the first 12 months of treatment
• the reduction in the dose of OCS achieved after the first 12 months of treatment is not maintained or improved subsequently
Approval duration of initial and renewals: 1 year
62

Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.